SG10201913477UA - G-quadruplex-containing antisense oligonucleotides - Google Patents

G-quadruplex-containing antisense oligonucleotides

Info

Publication number
SG10201913477UA
SG10201913477UA SG10201913477UA SG10201913477UA SG10201913477UA SG 10201913477U A SG10201913477U A SG 10201913477UA SG 10201913477U A SG10201913477U A SG 10201913477UA SG 10201913477U A SG10201913477U A SG 10201913477UA SG 10201913477U A SG10201913477U A SG 10201913477UA
Authority
SG
Singapore
Prior art keywords
quadruplex
antisense oligonucleotides
containing antisense
oligonucleotides
antisense
Prior art date
Application number
SG10201913477UA
Inventor
Anh Tuan Phan
Kah Wai Lim
Vee Vee Cheong
Christopher Brian Henry Jacques Lech
Brahim Heddi
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG10201913477UA publication Critical patent/SG10201913477UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201913477UA 2016-04-29 2017-05-02 G-quadruplex-containing antisense oligonucleotides SG10201913477UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201603451U 2016-04-29

Publications (1)

Publication Number Publication Date
SG10201913477UA true SG10201913477UA (en) 2020-02-27

Family

ID=60160837

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809002RA SG11201809002RA (en) 2016-04-29 2017-05-02 G-quadruplex-containing antisense oligonucleotides
SG10201913477UA SG10201913477UA (en) 2016-04-29 2017-05-02 G-quadruplex-containing antisense oligonucleotides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201809002RA SG11201809002RA (en) 2016-04-29 2017-05-02 G-quadruplex-containing antisense oligonucleotides

Country Status (4)

Country Link
US (1) US11390867B2 (en)
EP (1) EP3449002A4 (en)
SG (2) SG11201809002RA (en)
WO (1) WO2017188898A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
BR112022011277A2 (en) 2019-12-09 2022-09-06 Astellas Pharma Inc ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR TARGET RNA EDITING
GB202014751D0 (en) * 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
CN113730593B (en) * 2021-08-02 2024-01-26 成都凌泰氪生物技术有限公司 Method for enhancing slow release capability of nucleic acid medicine
CN116262917A (en) * 2021-12-14 2023-06-16 成都凌泰氪生物技术有限公司 G-quadruplex-containing nucleic acids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
DK1695979T3 (en) 1991-12-24 2011-10-10 Isis Pharmaceuticals Inc Gapped modified oligonucleotides
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
DK1501848T3 (en) 2002-05-08 2007-10-22 Santaris Pharma As Synthesis of locked nucleic acid derivatives
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
EP2019692B1 (en) 2006-05-05 2014-06-04 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gccr
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
KR100998365B1 (en) * 2009-06-29 2010-12-06 압타바이오 주식회사 Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof
US9689025B2 (en) 2009-08-07 2017-06-27 Nec Solution Innovators, Ltd. Nucleic acid element for use in analysis, and analytical method, analytical reagent, and analytical instrument using same
CN111700901A (en) 2010-01-08 2020-09-25 Ionis制药公司 Modulation of angiopoietin-like 3 expression
EP3192800A1 (en) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP2697243B1 (en) 2011-04-01 2018-10-31 Ionis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
SG10201705094SA (en) * 2012-12-21 2017-07-28 Univ Nanyang Tech Site-specific induction of bimolecular quadruplex-duplex hybrids and methods of using the same
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
SG11201508111QA (en) 2013-04-26 2015-10-29 Univ Nanyang Tech Modified g-quadruplex nanoparticles
AU2014259755B2 (en) 2013-05-01 2018-08-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US20150050738A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Compositions and methods for modulating rna
WO2015153975A1 (en) * 2014-04-03 2015-10-08 Aurasense Therapeutics, Llc Self assembling nucleic acid nanostructures

Also Published As

Publication number Publication date
US20210139893A1 (en) 2021-05-13
US11390867B2 (en) 2022-07-19
WO2017188898A1 (en) 2017-11-02
EP3449002A4 (en) 2019-09-25
SG11201809002RA (en) 2018-11-29
EP3449002A1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
HK1258758A1 (en) Branched oligonucleotides
IL268422A (en) Targeted oligonucleotides
HK1252970A1 (en) Defined multi-conjugate oligonucleotides
IL256634A (en) Therapeutic oligonucleotides
IL257091B (en) Targeted oligonucleotides
ZA201700142B (en) Antisense nucleic acids
IL247663A0 (en) Antisense nucleic acids
HK1257273A1 (en) Combination comprising immunostimulatory oligonucleotides
GB201503408D0 (en) Oligonucleotides
GB201711809D0 (en) Antisense oligonucleotide
IL258065B (en) Antisense nucleic acids
GB201507926D0 (en) Improved treatments using oligonucleotides
GB201504124D0 (en) Oligonucleotides
SG10201913477UA (en) G-quadruplex-containing antisense oligonucleotides
EP3532617A4 (en) Antisense oligonucleotides
PL3329004T3 (en) Therapeutic oligonucleotides
IL263852B (en) Oligonucleotides comprising modified nucleosides
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB201714330D0 (en) Oligonucleotides
GB201814450D0 (en) Antisense oligonucleotides
GB201516505D0 (en) Antisense oligonucleotides
GB201508733D0 (en) Antisense oligonucleotides
SG11201912447RA (en) Tyrosinase antisense oligonucleotides
EP3323892A4 (en) Antisense oligonucleotide inhibiting 2gpi expression
GB201504642D0 (en) Towelling